New paradigm in the treatment of hepatic colorectal metastases: A surgeon's perspective

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Curative resection of liver metastases from colorectal cancer is associated with high 5-year overall survival rates, making complete resection and conversion of unresectable disease to resectable disease goals of therapy for liver metastases. With advances in technology and surgical approaches, the definition of "resectable" has undergone a paradigmatic shift from focusing on "what comes out" to "what stays in." The current objective is to remove all known disease while leaving adequate remnant liver. This latter approach requires multidisciplinary efforts and extensive preoperative planning. When disease is not thought to be initially resectable, methods for converting initially unresectable to resectable disease include tumor downsizing (eg, via neoadjuvant chemotherapy), increasing remnant hepatic reserve (eg, via staged resection or portal vein embolization), and ablative techniques. Systemic chemotherapy for metastatic disease has improved in recent years, and there is accumulating evidence that adjuvant therapy improves outcome. However, considerable work remains in defining the optimal use of chemotherapy for resectable disease.

Original languageEnglish (US)
Pages (from-to)9-14
Number of pages6
JournalCommunity Oncology
Volume5
Issue number6 SUPPL. 6
StatePublished - Jun 2008

Fingerprint

Neoplasm Metastasis
Liver
Drug Therapy
Therapeutics
Portal Vein
Surgeons
Colorectal Neoplasms
Technology
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

New paradigm in the treatment of hepatic colorectal metastases : A surgeon's perspective. / Choti, Michael A.

In: Community Oncology, Vol. 5, No. 6 SUPPL. 6, 06.2008, p. 9-14.

Research output: Contribution to journalArticle

@article{9bd92b458fd5404684f921126a34e239,
title = "New paradigm in the treatment of hepatic colorectal metastases: A surgeon's perspective",
abstract = "Curative resection of liver metastases from colorectal cancer is associated with high 5-year overall survival rates, making complete resection and conversion of unresectable disease to resectable disease goals of therapy for liver metastases. With advances in technology and surgical approaches, the definition of {"}resectable{"} has undergone a paradigmatic shift from focusing on {"}what comes out{"} to {"}what stays in.{"} The current objective is to remove all known disease while leaving adequate remnant liver. This latter approach requires multidisciplinary efforts and extensive preoperative planning. When disease is not thought to be initially resectable, methods for converting initially unresectable to resectable disease include tumor downsizing (eg, via neoadjuvant chemotherapy), increasing remnant hepatic reserve (eg, via staged resection or portal vein embolization), and ablative techniques. Systemic chemotherapy for metastatic disease has improved in recent years, and there is accumulating evidence that adjuvant therapy improves outcome. However, considerable work remains in defining the optimal use of chemotherapy for resectable disease.",
author = "Choti, {Michael A.}",
year = "2008",
month = "6",
language = "English (US)",
volume = "5",
pages = "9--14",
journal = "Community Oncology",
issn = "1548-5315",
publisher = "BioLink Communications",
number = "6 SUPPL. 6",

}

TY - JOUR

T1 - New paradigm in the treatment of hepatic colorectal metastases

T2 - A surgeon's perspective

AU - Choti, Michael A.

PY - 2008/6

Y1 - 2008/6

N2 - Curative resection of liver metastases from colorectal cancer is associated with high 5-year overall survival rates, making complete resection and conversion of unresectable disease to resectable disease goals of therapy for liver metastases. With advances in technology and surgical approaches, the definition of "resectable" has undergone a paradigmatic shift from focusing on "what comes out" to "what stays in." The current objective is to remove all known disease while leaving adequate remnant liver. This latter approach requires multidisciplinary efforts and extensive preoperative planning. When disease is not thought to be initially resectable, methods for converting initially unresectable to resectable disease include tumor downsizing (eg, via neoadjuvant chemotherapy), increasing remnant hepatic reserve (eg, via staged resection or portal vein embolization), and ablative techniques. Systemic chemotherapy for metastatic disease has improved in recent years, and there is accumulating evidence that adjuvant therapy improves outcome. However, considerable work remains in defining the optimal use of chemotherapy for resectable disease.

AB - Curative resection of liver metastases from colorectal cancer is associated with high 5-year overall survival rates, making complete resection and conversion of unresectable disease to resectable disease goals of therapy for liver metastases. With advances in technology and surgical approaches, the definition of "resectable" has undergone a paradigmatic shift from focusing on "what comes out" to "what stays in." The current objective is to remove all known disease while leaving adequate remnant liver. This latter approach requires multidisciplinary efforts and extensive preoperative planning. When disease is not thought to be initially resectable, methods for converting initially unresectable to resectable disease include tumor downsizing (eg, via neoadjuvant chemotherapy), increasing remnant hepatic reserve (eg, via staged resection or portal vein embolization), and ablative techniques. Systemic chemotherapy for metastatic disease has improved in recent years, and there is accumulating evidence that adjuvant therapy improves outcome. However, considerable work remains in defining the optimal use of chemotherapy for resectable disease.

UR - http://www.scopus.com/inward/record.url?scp=46049095664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46049095664&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:46049095664

VL - 5

SP - 9

EP - 14

JO - Community Oncology

JF - Community Oncology

SN - 1548-5315

IS - 6 SUPPL. 6

ER -